As of Q1'26 (2025-12-31), CLSK reported total operating expenses of 20.85M USD, entirely attributed to SG&A Expenses, with R&D Expenses remaining at 0 USD. This marks the highest quarterly operating expense in the period shown, continuing a trend of increasing SG&A costs. From Q2'23 to Q1'26, operating expenses have shown a consistent upward trajectory, rising from 4.33M USD to 20.85M USD. The data reveals no allocation to R&D Expenses throughout the entire period, indicating that all operating costs are driven by SG&A. Notably, there were significant jumps in SG&A Expenses in Q3'24 and Q3'25, suggesting periods of accelerated spending. Overall, the chart highlights a strong growth in operating expenses, with a clear emphasis on SG&A as the sole contributor.